Publication
Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerB Lymphoblastic Leukemia/Lymphomacivic_curation1.00
- drugImatinibcivic_curation1.00
- geneABL1civic_curation1.00
- variantABL1 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27125982
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL1 Fusion1 | ||||||||
| Imatinib | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7783This case report describes a 15 year old patient with relapsed B-ALL positive for the RCSD1-ABL1 fusion, who was successfully treated with chemotherapy with addition of imatinib; the patient remained … (full text at CIViC) PMID 27125982 · Perwein et al., 2016 · Open in CIViC | civic |
| ABL2 Fusion1 | ||||||||
| (oncogenic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Oncogenic | C | N/A N/A | 3 | rejected | civic | |
| RCSD1 RCSD1::ABL11 | ||||||||
| Imatinib | Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED | Predictive | C | Supports Sensitivity Response | 3 | rejected | EID7782In the case report, it has been stated that the patient with known B-cell precursor ALL was induced to remission by imatinib, a tyrosine kinase inhibitor that affects the following eight ABL1 fusion p… (full text at CIViC) PMID 27125982 · Perwein et al., 2016 · Open in CIViC | civic |